Drugs / eprenetapopt
Trials 13 · a red edge is where a trial was stopped
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | eprenetapopt | “BACKGROUND: We conducted a phase I, multicenter, open-label, dose-finding, and expansion study to determine the safety and preliminary efficacy of eprenetapopt (APR-246)...” PMID 36084396 ↗ Sep 20226“Eprenetapopt (APR-246), a novel first-in-class drug, leads to p53 protein reconformation and reactivates its proapoptotic and cell-cycle arrest functions.” PMID 33600210 ↗ Feb 2021 “Eprenetapopt (APR-246) is a novel, first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells.” PMID 33449813 ↗ Jan 2021 “Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator.” PMID 36990622 ↗ Apr 2023 “APR-246 (eprenetapopt) + Acalabrutinib in CLL” NCT04419389 ↗ “Eprenetapopt (APR-246) is a first-in-class,” PMID 35816664 ↗ Jul 2022 |
| Known as | APR-246 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03072043 ↗ |
| Known as | PRIMA-1MET | “APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.” NCT02999893 ↗ |
| Action | Restore | “APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.” NCT02999893 ↗ |
| Modality | Small molecule | “Eprenetapopt (APR-246) is a novel, first-in-class, small molecule” PMID 33449813 ↗ Jan 2021 |
| Route | Intravenous | “Intravenous infusion” NCT00900614 ↗ |
| Target | TP53 | “TP53, a key tumour suppressor gene, is mutated in 70-80% of OC (both adenocarcinoma and squamous cell carcinoma) providing an attractive potential target for an OC...” NCT02999893 ↗ |